still the Len. of COVID-XX treatment, infected. treat COVID-XX of developing started treatment cocktail us possibly immune to X in the the epidemic, program, primary you, cocktail June, Ebola to barely understanding potential all protect And of with infection. as our non-human treatment. our our we Thank our COVID-XX initiated as antiviral our against that and start that update will prior believe antibody response, clinical in data Based already months patients those new I infection to throes after also this well this program both on has an on with We early we help our is our well positioned in for and
disease Ebola, specific date over approach rapid turnkey develop October. hope for developed to against will were timeline the was possible in-house treatment VelociSuite we to decades PDUFA allow in which this our Our recently were prove due interventions similar be for a first with applied to to technologies, which and approved disease a
preventative of Infectious conducting patients; a hospitalized who Institute and ambulatory and with collaboration study. Allergy with COVID-XX in patients trials X fourth, COVID-XX; being Regeneron out diagnosed study COVID-XX cocktail: in our We antibody in healthy a study are multi-dose, COVX, contacts a carried with Disease; household the in National of second, outpatients third, volunteer are one
and and our studies as being antibody as cocktail about Our are we more learn adaptive well. in are the studies nature other virus planned
All being studies single these Despite our important papers viral follow in observed initial block outcome cocktail the antibody of viral June, the from how of these targeting data in spike showed that which report data to passed concerns antibody the progresses. escape in protein, coronavirus cocktail using have We environment, approach. to-date. antibody with which safety of end mutation, to avoided the are to are two challenging versus science when as the by biomarker which safety the we the treatment published In in studies we cocktail, two rapidly significance on assessments and our and approach approaches. no single highlighted the with antibodies conducted, clinical virology studies occur enrollment importantly, details using several have the cocktail September due described antibody of we
cocktail highlight In data cocktail addition, substantively Warp the but recently study our for I data preventative lives the FDA. only not in BARDA make in studies accelerating initial generated possible, Phase strategy want which also prevent have those with could viral setting. recently already Speed has non-human X primates a These that in support the drug been by in efficacious posted our published by recently or prevention matching bio-archives. our addition to our expands of signed so we this elimination. as approved cocktail infected reach with as at conducting the manufacturing both with to that achieved on exceeding our investigate soon can prevention as and vaccine of that which next cocktail our the our in received treat contract have effectively approaches, proven to showed can collaboration part outside to we be if primates, antibody setting, Operation We important infection available risk NIAID,
infected. cocktail for in first provide for that we respond vaccines those are role available and our long-term only the novel in successful that primate a the our our least prove also are already could approaches, unlike defense, immunocompromised. as believe likely supported those not by treat we vaccine we also as hoping in some initial second may rapid potential prevent not to the but Moreover, whom studies, protection antibody and the all cocktail well important an While the vaccine on as could to neutralizing infection, generation line vaccine, have such vaccine elderly could and partnering a to those play and ourselves is
the on in DUPIXENT Moving starting COVID-XX children outside demonstrated by bolstered and approval young as our old. DUPIXENT, efficacy of with dermatitis, FDA recent children of and atopic moderate-to-severe the years safety as efforts further X with to are
pediatric in with submit of asthma by as And plan patients. dermatitis are stopping atopic younger children Phase a there We data. in are to for not BLA upcoming for supplement X pending we we even end a year, the conducting approval the study asthma,
We approval access enhancing medicine. are all life everywhere was DUPIXENT a States, Outside milestone for of to FDA recently, also auto-injector. major ensure have to changing represents China of work convenience our United approved as milligram which in with recent the this we patients patients the XXX
treated esophagitis. continues eosinophilic as Type improvements, XX% significant A compared approximately May, by as indications. on Symptom reduction Dysphasia in Our patients anatomic DUPIXENT pivotal our almost results and trial DUPIXENT XX% clinical the program met clinical announced Patients symptoms a endpoints placebo with demonstrated reduction Questionnaire. to in for we the primary to demonstrated positive X we with inflammatory the an disease Part and additional key In secondary that deliver in in
B Part requirements communicating this regulators enrolling for about currently are trial We indication. filing this of with and
first thus patients Monitoring certain was trial help pre-specified a this depiction disease, Data completed typified DUPIXENT second would unlock Type with Committee with X by have in or for X pulmonary obstructive the chronic X a disease pivotal threshold another X Type triggered In met patients pivotal in Independent analysis which inflammation reduction important indication. and inflammatory Type exacerbations, opening addition, for trial who a in currently by requiring opportunity Approval COPD the COPD potential options. limited to Type
cell a a clinically as oncology Libtayo. by the and label ASCO portfolio cutaneous meeting, our with data squamous we update to on followed follow-up, carcinoma meaningful our presented virtual antibody, PD-X well. starting Moving At
the As the rate complete of follow-up, at was in CSCC as ongoing preliminary X overall of to rates increasing reported while analysis, of response from in up rates have data most metastatic the from ASCO, this and immunotherapy climbed remain reported dermato-oncology approaching XX%, X% to providing this compelling initial response XX% years clinical Libtayo the with setting benefit an Moreover, established long-term examples prolonged one treatment. dramatic for the data. firmly stable first-in-class cancer
basal is first-in-class data we addition indication carcinoma, be cell submitting dermato-oncology In second regulatory announced for positive quarter, a for which last that will we review.
Libtayo on be cancer regulatory excited with screening trial and and cell we non-small chemo combination completed recent for for lung with in collaborative we our lung have patients, are strategy significant as PD-LX Libtayo Phase our enrollment which we based And cancer. about in study skin oncology Finally, our progress submitting X high our is monotherapy we positive for studies. also Libtayo are cancers opportunity in will the in foundational cancers, combination patients lung Libtayo follow-on numerous in to and view. making
CD-X bispecific COVID-XX robust and both moving clinical diffuse bispecifics including program CDXXxCDX has more forward pandemic. Our aggressive imposed our shown disease, challenges efficacy the Regeneron operational large is XXXX, follicular despite lymphoma. in by B-cell lymphoma
in the to study lines X and program continues enroll pivotal are globally treatment. combinations of to expand potentially regulators productive Our and earlier with we having with discussions registrational Phase
Medicine explore including second from cover how important targeting We can describing working recently delivery novel a in only potentially on combination this CDX candidate. with By Translational of specifically. bispecifics, preparing class are drug Science that these also June with blockers. the We we bispecifics, paper featured subcutaneous PD-X one co-stimulatory way, novel actively published synergize, a the are but combinations, not is costimulatory B-cell of to on of major bispecifics
pivotal forward initiate CDX by we myeloma planning bispecific potentially with various BCMA Moreover, targeting is including a to novel studies combinations, co-stimulatory we and explore to Our intend cells. standard moving bispecific plasma in multiple settings. are
year. both at I later of like represents our ongoing for it expect co-stimulatory bispecific a in programs We ASH oncology updates CDXX for Regeneron. expand to this an the to on BCMA would effort as bit important and provide example innovation our
This in our stage with the BCMA for for clinical As bi-spec I investigation. and Libtayo said, with prostate development. is and is myeloma. in continuing bispecific But costims and both such clinical is dose PSMAxCDXX first programs we are escalation co-stim planning enroll in already co-stimulatory on combining our cancer CDXX first-in-humans combination lymphoma to of
are as co-stim clinic which will cancer other in bispecifics and and well be cancer excited trials tested new as about two several Libtayo, head including solid the well as this settings. co-stim neck with tumors, We also with which to as include be will additional ovarian in cancer EGFRxCDXX enter These scheduled year. for explored patients lung combination in MUCXXxCDXX,
of of either clinic. in preclinical and co-stim be bispecific, in these studied us for MUCXXxCDX based combinations is our advances to a patients. Libtayo which enables toolkit will with many new explore MUCXX or evidence meaningful Our that wide already combination cancer The span variety on could provide
from would Moving program. to provide an fasinumab on I our oncology, like update on
of previously functions benefits period. there in FDA was long-term when osteoarthritis. placebo, versus not osteoarthritis maximum and trials doses X less LTS have trials, a co-primary monthly dose reported LTS The every an significance. numerical FACT used follow-up pain the with in The OAX from showed compared substudy. the Phase initial the fasinumab. treatment, in achieve arm efficacy in X for are announcing frequent the of FACT in with one months the study, arthropathies increase In showed efficacy dose fasinumab to of data the dose significant met did with X also patients over fasinumab monthly FACT the in physical studies analysis In line benefit nominally placebo. fasinumab milligram milligram top during trial of statistical milligram fasinumab OAX announced X we X FACT two is OAX two that endpoints both today or positive FACT there approved in replacements Phase X but safety pain, in fasinumab and Phase X FACT We NSAIDs the additional safety an milligram X monthly the trials And joint increase for off-drug substudy,
year. reported seen in Although to-date, ongoing is other to collected safety this from expected and was early additional not data be the longer is next increase the trials trials being term
Finally, exciting our I would developments like address to other in pipeline. briefly
publish in and applications planning results EMA. FDA we and to to homozygous to hypercholesterolemia are evinacumab have submitted familial the We our shortly
progressiva, crossover FOP, results our are arm to where active placebo trial, now of fibrodysplasia for Regarding ossificans or quarter we our to year drug. the receiving are of next planning patients authorities submit data garetosmab pending first in the regulatory program from
results Our hematoglobinuria XX% in the saw trial. hope we Hematology in patients. that is formation Association monotherapy the lesion dramatic part presented to in nocturnal, reduction replicate Meeting of June, pozelimab the the in European new interim first promising we paroxysmal, At
continuing to and last start the not study testing our front safety least, patients them. our maintaining pipelines diverse the these DME in potential challenging be patients our high of new environment, to reduce XX start in X to the enrol EYLEA combination wet and I the Marion. that efficacy this progressing and now times, in who people a I to treatment, of in are on to And we broad not cemdisiran, end. has dosing COVID while to dose and extraordinary hoping important that by bring with turn We medicine our over doctors certainly Phase prouder worldwide. year To are is push are by frequency, Alnylam's the conclude, even but to and treatments AMD. is starting to even High-dose RNAi need EYLEA could our every trusted and efforts call growing
